Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies

Leukemia

Volumn 23, Issue 7, 2009, Pages 1278-1287

  Triplett, B M ^a   Horwitz, E M ^b   Iyengar, R ^c   Turner, V ^c   Holladay, M S ^c   Gan, K ^c   Behm, F G ^d   Leung, W ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; HLA C ANTIGEN; HLA C2 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKP44; NATURAL KILLER CELL RECEPTOR NKP46; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CELL COUNT; CELL FUNCTION; CELL RECONSTITUTION; CHILD; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RECURRENCE RISK; SURVIVAL RATE; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 67650930909     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.21     Document Type: Article

References (68)

1. Copelan E. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
3. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron J, Ifrah N, Milpied N et al Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematology malignancy: A prospective study from the French society of bone marrow transplantation and cell therapy. J Clin Oncol 2006; 24: 5695-5702.
4. National Marrow Donor Program. Trends in allogeneic transplants. http://www.marrow.org/PHYSICIAN/URD_Search_and_Tx/ Number_of_Allogeneic_Tx_Perfor/index.html. Accessed 6 February 2008.
5. Auletta J, Lazarus H. Immune restoration following hematopoietic stem cell transplantation: An evolving target. Bone Marrow Transplant 2005; 35: 835-857.
6. Parham P, McQueen KL. Alloreactive killer cells: Hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108-122.
7. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
8. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008; 20: 581-587.
9. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
10. Uhrberg M, Valiante N, Shum B, Shilling H, Lienert-Weidenbach K, Corliss B et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7: 753-763.
11. Leung W, Iyengar R, Triplett B, Turner V, Behm F, Holladay M et al Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545.
12. Blomberg K, Hautala R, Lovgren J, Mukkala V, Lindqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand. J Immunol Methods 1996; 193: 199-206.
13. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
14. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley, John, and Sons, Inc: New York, New York, 1980.
15. Leung W, Turner V, Richardson S, Benaim E, Hale G, Horwitz E et al Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 2001; 62: 399-407.
16. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh of cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29 1656-1666.
17. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065-2072.
18. Lowe E, Turner V, Handretinger R, Horwitz E, Benaim E, Hale G et al T-cell alloreactivity dominates natural killer cell allo-reactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haemol 2003; 123: 323-326.
19. Appelbaum FR. Hematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
20. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
21. Murphy WJ, Longo DL. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997; 157 167-176.
22. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
23. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
24. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al. International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828-836.
25. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061.
26. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97: 539-542.
27. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
28. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Jikakli AA, Rouas-Freiss N et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: Immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105: 4135-4142.
29. Cooley S, McCullar V, Wangen R, Bergemann T, Spellman S, Weisdorf D et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
30. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA- mismatched/ haploidentical blood and marrow transplantation: Analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome. Biol Blood Marrow Transplant 2007; 13: 734-744.
31. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169: 4253-4261.
32. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE et al DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197: 245-255.
33. Trompeter HI, Gómez-Lozano N, Santourlidis S, Eisermann B, Wernet P, Vilches C et al. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol 2005; 174: 4135-4143.
34. Davies GE, Locke SM, Wright PW, Li H, Hanson RJ, Miller JS et al. Identification of bidirectional promoters in the human KIR genes. Genes Immun 2007; 8: 245-253.
35. Li H, Pascal V, Martin MP, Carrington M, Anderson SK. Genetic control of variegated KIR gene expression: Polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet 2008; 4: E1000254.
36. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001; 166: 2992-3001.
37. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007; 68: 309-323.
38. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C et al Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006; 107: 1230-1232.
39. De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S et al Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 2005; 65: 519-528.
40. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38: 437-444.
41. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdonck LF, Tilanus MG. Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol 2008; 45: 2255-2261.
42. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H et al. Low number of donor activating killer immunoglobulinlike receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030.
43. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004; 63: 204-211.
44. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528.
45. Giebel S, Nowak I, Wojnar J, Markiewicz M, Dziaczkowska J, Wylezol I et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 2006; 38: 287-291.
46. Kim HJ, Choi Y, Min WS, Kim TG, Cho BS, Kim SY et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 2007; 84: 1082-1091.
47. Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H et al. Japan Marrow Donor Program. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14: 75-87.
48. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
49. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical stem cell transplantation. Leukemia 2005; 19: 1446-1451.
50. Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005; 102: 13224-13229.
51. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007; 179: 854-868.
52. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151-158.
53. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661-3667.
54. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109: 323-330.
55. Vitale C, Chiossone L, Morreale G, Lanino E, Cottalasso F, Moretti S et al. Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: Analysis of the surface expression and function of activating NK receptors. Mol Immunol 2005; 42: 405-411.
56. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073.
57. Prlic M, Blazar BR, Farrar MA, Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003; 197: 967-976.
58. Jamieson AM, Isnard P, Dorfman JR, Coles MC, Raulet DH. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol 2004; 172: 864-870.
59. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
60. Nguyen S, Kuentz M, Vernant JP, Dhedin N, Bories D, Debre P et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008; 22: 344-352.
61. Leung W, Iyengar R, Leimig T, Holladay MS, Houston J, Handgretinger R. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005; 54: 389-394.
62. Juliusson G, Theorin N, Karlsson K, Frödin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006; 37: 503-510.
63. Penack O, Fischer L, Stroux A, Gentilini C, Nogai A, Muessig A et al Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 377-383.
64. Chiossone L, Vitale C, Cottalasso F, Moretti S, Azzarone B, Moretta L et al. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: Evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 2007; 109: 3767-3775.
65. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112: 2990-2995.
66. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant 2008; 14: 290-300.
67. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: Effects of endogenous flt3 ligand. Blood 2004; 103: 3860-3868.
68. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong ASM et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21: 2145-2152.